Ann: Promising Interim Results from TAVR Animal Study, page-3

This seems to be the best news we've had for a while.
The piece I've cut and pasted below makes me feel hopeful.....if they can possibly bring things forward a bit sooner, a company maker.

“Calcification is a major issue for surgeons and patients today when treating valvulardisease. Our ADAPT® tissue is the only product of its kind that has data demonstrating tenyears without calcification or degradation. Combining this unique benefit with the first andonly single piece 3D valve could be a major disruption in the treatment strategies for patientsin the future,” said Wayne Paterson, Admedus CEO.“ADAPT® TAVR would be a breakthrough for patients needing valve replacement. TheTAVR market is expected to be $US12 billion by 2025. If the earlier results translate to trueclinical superiority, ADAPT® TAVR could be well placed to be the market leader.
----------------------------------------------------

Regards
Dabru